Drugs / anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00938626 | Oct 2009 → Oct 2011 | plasma cell myeloma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00938626 ↗ |
| Action | Deplete | “the ability of peripheral blood mononuclear cells to kill multiple myeloma cell lines” NCT00938626 ↗ |
| Route | Intravenous | “anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks” NCT00938626 ↗ |